MENU
Showcases Stock ranks Forex

Amicus Therapeutics (FOLD)
11.78  -0.08 (-0.67%) 03-28 16:00
Open: 11.87 Pre. Close: 11.86
High: 11.93 Low: 11.485
Volume: 2,399,468 Market Cap: 3,480(M)
Stock Technical Analysis
Overall:     
Target: Six months: 15.17
One year: 16.38
Support: Support1: 11.32
Support2: 9.42
Resistance: Resistance1: 12.99
Resistance2: 14.02
Pivot: 11.75
Moving Averages: MA(5): 11.63
MA(20): 12.06
MA(100): 12.36
MA(250): 12.22
MACD: MACD(12,26): -0.35
Signal(12,26,9): -0.36
%K %D: %K(14,3): 26.08
%D(3): 16.56
RSI: RSI(14): 42.87
52-Week: High: 14.57
Low: 9.7
Change(%): 8.0
Average Vol(K): 3-Month: 3103
10-Days: 2643
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 11.958 - 12.017 12.017 - 12.064
Low: 11.319 - 11.398 11.398 - 11.462
Close: 11.668 - 11.789 11.789 - 11.888
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ FOLD ] has closed below upper band by 47.2%. Bollinger Bands are 51% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Stock chart
Stock News
Thu, 28 Mar 2024
Amicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5% - MarketBeat

Wed, 27 Mar 2024
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough - Simply Wall St

Wed, 27 Mar 2024
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Vanguard Group Inc. - Defense World

Wed, 27 Mar 2024
Vanguard Group Inc. Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Wed, 06 Mar 2024
Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD) - Yahoo Finance

Tue, 05 Mar 2024
Amicus Therapeutics Stock Sees RS Rating Improve To 74 - Investor's Business Daily

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 295.38
Shares Float (M) 222.12
% Held by Insiders 0.75
% Held by Institutions 109.74
Shares Short (K) 30910
Shares Short Prior Month (K) 24400
Stock Financials
EPS -0.510
Book Value (p.s.) 0.550
Profit Margin -37.96
Operating Margin -3.21
Return on Assets (ttm) -6.1
Return on Equity (ttm) -107.0
Qtrly Rev. Growth 30.6
Gross Profit (p.s.)
Sales Per Share 1.352
EBITDA (p.s.) -0.222
Qtrly Earnings Growth
Operating Cash Flow (M) -69.09
Levered Free Cash Flow (M) -25.89
Stock Valuation
PE Ratio -23.10
PEG Ratio
Price to Book value 21.42
Price to Sales 8.71
Price to Cash Flow -50.36
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android